CCSC

National Hemophilia Foundation

Website provided by National Hemophilia Foundation and its education partners

HTC Success in a Value-Based Health Care Environment: Findings from the Comprehensive Care Sustainability Collaborative

Live Webcast
Thursday, January 23, 2020
12:00 pm-1:30 pm ET

Download the slides now:

 

“I would like to say thank you to all of the CCSC faculty for their considerable work on this. As an HTC with in house pharmacy, we are constantly facing tightening employer networks. Employers are told by their PBM’s that an exclusive network will save the employer money. What CCSC has done is to open up the conversation with these employers to show that allowing HTCs in network will save them considerable money not only on the pharmacy side but in overall patient management and outcomes vs. an exclusive specialty pharmacy.”

Rebecca Burns
Executive Director
Bleeding and Clotting Disorders Institute

***Sign up to become a member and receive updates, access to useful resources, and practice tools.*** 

Who Should Attend

  • Hemophilia Treatment Center Providers and Administrators
  • Managed Care and Other Payer Professionals involved in the management of patients with hemophilia

Program Overview

Learn how the Comprehensive Care Sustainability Collaborative (CCSC) provides a unique forum for HTC clinicians and allied health care professionals to collaborate with payers to facilitate the sustainability of the HTC comprehensive care model. The aim of CCSC is to provide payers, purchasers, and other key health care decision makers with knowledge and skills crucial for managing the costs associated with hemophilia and to recognize the value of HTC services. Learn about how you can prepare your HTC to thrive in the ever-changing health care landscape.

Educational Objectives

  • Describe employer challenges related to managing the rising drug spend related to bleeding disorders
  • Discuss opportunities for collaborating with payers for the management of bleeding disorders
  • Evaluate what impels payers to make network inclusion/exclusion decisions for high-cost conditions
  • Outline examples of value-driven HTC services that are able to meet future needs for the care of patients with bleeding disorders
  • Explain how participation in CCSC can foster HTC exposure and sustainability to promote network inclusion and favorable contract negotiations with payers and purchasers

Distinguished Faculty Presenters

Kollet Koulianos, MBA
Senior Director Payer Relations
National Hemophilia Foundation

Edmund Pezalla, MD, MPH
CEO
Enlightenment Bioconsult, LLC

Troy Ross
President & CEO
Mid-America Coalition on Health Care

Michael Tarantino, MD
Professor of Pediatrics
Division of Pediatric Hematology/Oncology
University of Illinois College of Medicine
Medical Director
Bleeding & Clotting Disorders Institute

Agenda

  • Opening Comments
    Kollet Koulianos, MBA

  • What Can CCSC Do For You?
    Michael Tarantino, MD

  • Revelations from Employer Views of the HTC Care Model
    Troy Ross

  • What Payers Need and How HTCs can Deliver It
    Edmund Pezalla, MD, MPH

  • HTC Examples of Value-Driven Care: What Does Success Look Like?
    Kollet Koulianos, MBA

  • Moderated Faculty Panel Discussion and Audience Q&A
    Entire Faculty Panel
  • Closing Comments

  • Post-activity Assessment and Evaluations

Click Here to Register Now!

Hardware/Software Requirements

Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Fee Information

There is no fee for this educational activity.

 
If you have any questions, please call (215) 619-8812 or email info@impactedu.net

Jointly provided by National Hemophilia Foundation and Impact Education, LLC®

CCSC is supported by charitable donations from founding supporter, Takeda, and additional support from Bayer, BioMarin, Genentech, Inc., Hemophilia Alliance, Pfizer Inc., Sanofi Genzyme, and Spark Therapeutics.

© 2020 National Hemophilia Foundation. All rights reserved.